Dicirenone |
Catalog No.GC35862 |
Dicirenone (SC26304) inhibits the effects of Aldosterone on urinary K+:Na+ ratios and the binding of [3H]Aldosterone to renal cytoplasmic and nuclear receptors.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 41020-79-5
Sample solution is provided at 25 µL, 10mM.
Dicirenone (SC26304) inhibits the effects of Aldosterone on urinary K+:Na+ ratios and the binding of [3H]Aldosterone to renal cytoplasmic and nuclear receptors.
Cytoplasmic binding of [3H]Aldosterone and [3H]Dicirenone is similar in magnitude and involves the same set of sites. Under three sets of conditions-(i) in the intact rat, (ii) in kidney slices, and (iii) in reconstitution studies (mixing prelabeled cytoplasm with either purified renal nuclei or chromatin), [3H]Dicirenone does not yield specific nuclear complexes in contrast to the reproducible generation of these complexes with [3H]Aldosterone. In glycerol density gradients, cytoplasmic [3H]Aldosterone receptor complexes sediment at 8.5 S and 4 S in low concentrations of salt and at 4.5 S in high concentrations of salt. Cytoplasmic [3H]Dicirenone receptor complexes sediment at 3 S in low concentrations of salt and 4 S in high concentrations of salt. These results are discussed in terms of an allosteric model of the receptor system. Administration of Dicirenone (SC-26304) alone in doses of 3-600 μg/100 g of body weight has no effect on urinary Na+:creatinine or K+:creatinine ratios. These results are expressed as urinary K+:Na+ ratios. Aldosterone (0.3 μg/100 g of body weight) increases the K+:Na+ ratio 5-fold. This increase is significantly inhibited by 180 μg/100 g of body weight of Dicirenone and completely inhibit by 600 μg/100 g of body weight. To correlate inhibitory action and receptor occupancy, the same doses of Dicirenone are given to rats injected with 0.036 μg of [3H]Aldosterone. A dose of 180 μg of body weight reduces specific binding of Aldosterone in cytoplasmic and nuclear fractions to less than half of the control levels and 600 μg/100 g of body weight eliminated specific binding. The dose of Aldosterone used in the physiological studies is about eight times that used in the binding studies, but both doses are well below saturating amounts[1].
[1]. Marver D, et al. Renal aldosterone receptors: studies with (3H)aldosterone and the anti-mineralocorticoid (3H)spirolactone (SC-26304). Proc Natl Acad Sci U S A. 1974 Apr;71(4):1431-5.
Cas No. | 41020-79-5 | SDF | |
Canonical SMILES | C[C@@]12[C@@]3(OC(CC3)=O)CC[C@@]1([H])[C@@]4([H])[C@]([C@@]5(C(C[C@H]4C(OC(C)C)=O)=CC(CC5)=O)C)([H])CC2 | ||
Formula | C26H36O5 | M.Wt | 428.56 |
Solubility | Soluble in DMSO | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.3334 mL | 11.667 mL | 23.334 mL |
5 mM | 0.4667 mL | 2.3334 mL | 4.6668 mL |
10 mM | 0.2333 mL | 1.1667 mL | 2.3334 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5
(Based on Reviews and 11 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *